lutetium Lu 177 JH040182

Lutetium Lu 177 JH040182 is a targeted radiopharmaceutical therapeutic candidate developed by Nucleic Bio (Jinghe Biological) for the treatment of advanced solid tumors. The agent consists of a ligand targeting Fibroblast Activation Protein (FAP) conjugated to the beta-emitting radioisotope lutetium-177 (Lu-177). FAP is a cell-surface glycoprotein that is highly overexpressed on cancer-associated fibroblasts (CAFs) within the tumor stroma of various epithelial cancers, while remaining largely absent in normal adult tissues. By binding to FAP, JH040182 delivers localized ionizing radiation directly to the tumor microenvironment, inducing DNA damage and cell death in both the stroma and adjacent malignant cells. The drug is currently being evaluated in Phase I/II clinical trials in China to determine its safety, radiation dosimetry, pharmacokinetics, and preliminary antitumor activity in patients with FAP-positive advanced malignant solid tumors.